Skip to content
    COR
    Earnings call· Dec 2024(Q1 FY25)

    Cencora, Inc. COR

    Feb 5, 2025 Source

    Executive summary

    Cencora Q1 FY25 — Strong U.S. Performance Drives Raised EPS Guidance

    Cencora delivered a strong Q1 FY25, driven by robust performance in its U.S. Healthcare Solutions segment, particularly from strong utilization trends and GLP-1 product sales, leading to a raised full-year EPS outlook. The company is strategically expanding its specialty leadership through MSO investments like RCA, while navigating headwinds in its international logistics business and managing cash flow timing.

    Highlights

    5

    • Consolidated revenue grew 13% to $81.5 billion in Q1 FY25.

    • Adjusted diluted EPS increased 14% to $3.73 in Q1 FY25.

    • U.S. Healthcare Solutions segment revenue was up 14% to $74 billion.

    • Full-year adjusted diluted EPS guidance was raised to $15.25-$15.55.

    • The acquisition of Retina Consultants of America (RCA) was completed on January 2, expanding leadership in specialty.

    Concerns

    4

    • Consolidated gross profit margin decreased 20 basis points to 3.11% due to increased low-margin GLP-1 sales and lower COVID-19 vaccine/therapy sales.

    • International Healthcare Solutions operating income decreased 3% on an as-reported basis due to subdued clinical trial activity in global specialty logistics and foreign currency impacts.

    • The global specialty logistics business (World Courier) experienced a challenging quarter due to subdued clinical trial activity.

    • Adjusted free cash flow was negative $2.8 billion in Q1 FY25 due to the timing of cash flows.

    Guidance & targets

    13
    CategoryTargetConfidence
    Adjusted diluted EPS
    $15.25 to $15.55
    high materiality
    High
    Consolidated revenue growth
    8% to 10%
    high materiality
    High
    U.S. Healthcare Solutions segment revenue growth
    9% to 11%
    high materiality
    High
    International Healthcare Solutions segment revenue growth (as-reported)
    4% to 5%
    medium materiality
    Medium
    International Healthcare Solutions segment revenue growth (constant currency)
    7% to 9%
    medium materiality
    High
    Consolidated operating income growth
    11.5% to 13.5%
    high materiality
    High
    U.S. Healthcare Solutions segment operating income growth
    14.5% to 16.5%
    high materiality
    High
    International Healthcare Solutions segment operating income growth (as-reported)
    flat year-over-year
    medium materiality
    Medium
    International Healthcare Solutions segment operating income growth (constant currency)
    approximately 5%
    medium materiality
    Medium
    Interest expense
    $290 million to $310 million
    medium materiality
    High
    Full-year average share count
    under 196 million shares
    low materiality
    High
    Adjusted free cash flow
    $2 billion to $3 billion
    high materiality
    High
    Adjusted diluted EPS growth
    mid-single digits
    medium materiality
    Medium

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    U.S. Healthcare Solutions
    Strong utilization trends, continued volume growth in GLP-1s, and growth in sales to specialty physician practices and health systems. Ex-GLP-1 revenue growth was 10%. Overcame COVID-related headwinds.
    Operating income growth: 10%GLP-1 sales growth: 53% YoYGLP-1 sales: $3.2 billion
    		$74 billion14%—$767 million
    International Healthcare Solutions
    Increased sales at European distribution business. Lower operating income at global specialty logistics business (World Courier) due to subdued clinical trial activity, partially offset by European distribution.
    Operating income growth: -3% (as-reported), 3% (constant currency)
    		$7.5 billion6% (as-reported), 9% (constant currency)—$182 million

    Operational metrics

    10
    Consolidated revenue growth excluding GLP-1s
    9%
    Q1 FY25

    Excluding sales of GLP-1s, our consolidated revenue growth would have been 9%.

    Consolidated gross profit
    $2.5 billionup 6%
    Q1 FY25

    Consolidated gross profit was $2.5 billion, up 6%.

    Consolidated operating expenses
    $1.6 billionup approximately 6%
    Q1 FY25

    Consolidated operating expenses were $1.6 billion, up approximately 6% due to higher distribution, selling and administrative expenses to support revenue growth.

    Net interest expense
    $28 milliondown 31%
    Q1 FY25

    Net interest expense was $28 million, down 31% due to higher interest income resulting from higher average investment cash balances and interest rates partially offset by an increase in interest expense.

    Diluted share count
    195.2 million3% decline compared to the prior year first quarter
    Q1 FY25

    Diluted share count was 195.2 million shares, a 3% decline compared to the prior year first quarter, driven by approximately $1.5 billion of opportunistic share repurchases during the period of February through October of 2024.

    Cash used in operations
    $2.7 billion
    Q1 FY25

    We used $2.7 billion of cash in our operations during the quarter.

    U.S. Healthcare Solutions segment revenue growth excluding GLP-1s
    10%
    Q1 FY25

    Excluding sales of GLP-1 products, U.S. segment revenue growth would have been 10% for the quarter.

    COVID-19 vaccine contribution
    about half that of the prior year quarterYoY
    Q1 FY25

    The contribution from COVID-19 vaccines was about half that of the prior year quarter.

    Exclusive COVID-19 therapies contribution
    $0.06
    Q1 FY24

    The first quarter of fiscal 2024 was the final quarter of contribution from exclusive COVID-19 therapies, which contributed $0.06 to our first quarter of fiscal 2024.

    Animal Health top line growth
    7%
    Q1 FY25

    The Animal Health business had 7% top line growth.

    Industry KPIs

    7
    MetricValueDetails
    EPS$3.73USD
    Gross margin3.11%%
    Debt leverageprioritize deleveraging
    Revenue net sales$81.5 billionUSD
    Effective tax rate20%%
    Free cash flow operating cash flow-$2.8 billionUSD
    Geographic regional revenue growth14%%

    Deals & partnerships

    2
    Retina Consultants of America (RCA)Acquisition of a leading retina MSO, differentiated by its leadership team, clinical excellence, premier physician partner practices and positioning at the forefront of retina innovation through its clinical research capabilities.

    Fits squarely into Cencora's strategy and growth by expanding leadership in specialty in a high-growth pharmaceutical-centric segment, building on services for customers and positioning well in a medical specialty that has seen significant innovation. RCA was already a distribution customer.

    OneOncologyInvestment in an oncology MSO.

    Helps Cencora understand the MSO business and aligns with its long-term commitment to support community providers.

    Risks & headwinds

    6
    GLP-1 product sales impact on gross marginQ1 FY25

    20 basis points decrease in consolidated gross profit margin

    Decline in COVID-19 vaccine and therapy salesQ1 FY25 and Q2 FY25

    Q1 FY25 vaccine contribution about half of prior year; $0.06 EPS headwind from exclusive therapies in Q1 FY24 (no contribution in Q1 FY25)

    Mitigation: Offset by strong broad-based growth in U.S. Healthcare Solutions segment.

    Subdued clinical trial activity impacting global specialty logisticsQ1 FY25, expected to improve later in FY25

    Lower operating income at global specialty logistics business (World Courier)

    Mitigation: Business remains focused on its pipeline and targeted regional prioritization of new volume growth.

    Strengthening U.S. dollarFY25

    Lowered International Healthcare Solutions segment revenue growth guidance (as-reported) to 4%-5% and operating income growth to flat YoY (as-reported)

    Negative adjusted free cash flow due to timingQ1 FY25

    -$2.8 billion in Q1 FY25

    Mitigation: Full-year adjusted free cash flow guidance of $2 billion to $3 billion reaffirmed.

    Increased interest expenseQ2 FY25 and FY25

    Expected to step up meaningfully in Q2 FY25; FY25 guidance raised to $290M-$310M

    What to watch in Q2 FY25

    5

    World Courier performance

    Later in fiscal 2025
    CurrentChallenging quarter, subdued clinical trial activity
    TargetImprovement in performance

    Why it matters

    Indicates recovery in global specialty logistics and broader pharma services demand.

    We expect to see business performance improve later in fiscal 2025 as demand for our premium service capabilities increases from its current levels.

    Q&A highlights

    6

    How Cencora is positioned to outgrow the specialty market, especially with MSO investments like OneOncology and RCA, and what drives this upside.

    Bob Mauch emphasized a pharmaceutical-centered strategy, focusing on innovation, expanding service offerings for manufacturers and providers, and leveraging a strong customer portfolio. He highlighted MSO services as a logical next step for supporting community providers, building on decades of experience.

    “We're going to stay focused on the pharmaceutical sector. And as you know, and as we all know, the innovation is significant there.”

    asked by Michael Cherny · answered by Robert Mauch

    2 min read6 chapters

    Detailed Narrative

    01

    Specialty Leadership Expansion

    Cencora is advancing its leadership in specialty healthcare, exemplified by the acquisition of Retina Consultants of America (RCA) on January 2. This move, following its investment in OneOncology, expands its MSO services, supporting community providers in high-growth pharmaceutical-centric segments like retina, which has seen significant innovation. The company believes this strategy aligns with its long-term commitment to supporting community providers and leveraging its pharmaceutical-centered approach.

    02

    Efficiency and Technology Focus

    The company is driving efficiency and productivity through advanced technology and expert teams, streamlining operations, optimizing business processes, and upgrading systems. This digital transformation strategy aims to enhance customer experience, accelerate decision-making, and ensure infrastructure resiliency. These efforts are focused on unlocking enterprise-wide value and meeting the evolving needs of partners.

    03

    Customer-Centric Innovation

    Cencora maintains a customer-centric mindset, collaborating with market-leading biopharma companies and providers. Its global footprint and expertise allow it to combine local knowledge with global infrastructure, supporting pharmaceutical innovation and growing higher-margin services, particularly in the European market. This differentiated approach is strategically important for long-term biopharma customer relationships.

    04

    GLP-1 and COVID-19 Impact

    Strong GLP-1 product sales significantly boosted U.S. revenue growth by 53% year-over-year, contributing $3.2 billion in Q1 FY25. However, these low-margin products, combined with reduced sales of commercial COVID-19 vaccines and the absence of exclusive COVID-19 therapies, negatively impacted consolidated gross profit margin by 20 basis points. The COVID-19 vaccine contribution in Q1 FY25 was about half that of the prior year, and exclusive therapies contributed $0.06 to EPS in Q1 FY24 but nothing in Q1 FY25.

    05

    International Segment Challenges

    The International Healthcare Solutions segment faced headwinds, with operating income down 3% as-reported, primarily due to a challenging quarter for the global specialty logistics business (World Courier). Subdued clinical trial activity and the strengthening U.S. dollar against other currencies impacted performance. Management expects business performance to improve later in FY25 as demand for premium services increases.

    06

    Capital Allocation and Deleveraging

    Following the RCA acquisition, Cencora will prioritize deleveraging in the near term. The company used $2.7 billion in operations, resulting in negative adjusted free cash flow of $2.8 billion in Q1 FY25 due to timing of📎 flows at calendar year-end. Despite this, Cencora reaffirms its full-year adjusted free cash flow guidance of $2 billion to $3 billion.

    AI-generated summary of the company’s earnings call. Not investment advice.